EN DE
Watch Biogen Pharmachem Industries Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Biogen Pharmachem Industries Limited (531752) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Biogen Pharmachem Industries Limited stock ₹0.20, price ₹0.28, that is 30.2% below the price, quality 38 out of 100. Rating: overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Health Care IN

BP Thin data Nov 16, 2026

Biogen Pharmachem Industries Limited

531752 · BSE

Expensive (fair value 30% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Generates free cash flow 
Mixed Growth (revenue 3y +31.5 %/yr in INR) 
Changed on Nov 2: ₹0.3995 → ₹0.1955 
Fair value ₹0.1955 · Overvalued 
Quality 38/100 
Falling price (downtrend) 
Trails peers (2/7) 
Narrow moat 36/100 · thin data
Thin data 
⚠ Dilution
Watch Biogen Pharmachem Industries Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1.56 ₹0.2057 Fair Value ₹0.1955 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range ₹0.2057 – ₹1.56 · fair‑value band ₹0.1615 – ₹0.2295 · the ₹0.2800 price screens above the ₹0.1955 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Biogen Pharmachem Industries in your weekly email

Every Wednesday you see whether Biogen Pharmachem Industries is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sun Techno Overseas Limited does not have significant operations. Previously it was engaged in trading shares, mutual funds, and other investments. The company was formerly known as Wellworth Overseas Limited and changed its name to Sun Techno Overseas Limited in August 2011.

Show moreShow less

Sun Techno Overseas Limited was incorporated in 1995 and is based in Rajkot, India.

Stock analysis

Biogen Pharmachem Industries Limited (531752) currently trades at ₹0.2800, while our model-based Fair Value estimate is ₹0.1955, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of ₹0.5300 per share, and 4 of the 15 models we run sit above the ₹0.2800 price.

Bear case: the Earnings-Based group reads lowest at ₹0.1250, and 11 of the 15 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹0.1615 (bear) to ₹0.2295 (bull), the price of ₹0.2800 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Health Care sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Biogen Pharmachem Industries Limited reported revenue of ₹0 in FY2026 versus ₹21.6M in FY2022. Reported net income was ₹9.6M in FY2026.

Key figures

Market cap ₹295M (≈ $3.1M) Micro · EPS (TTM) ₹−0.0018 · Return on assets (EBIT) 0.9% (5-year average) · Free cash flow ₹15.7M · Net debt ₹534K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Health Care peers we cover trades at −38% fair-value upside, at −30%, 531752 screens cheaper than that median.

Fair Value models

Bear ₹0.1615 Fair Value ₹0.1955 Bull ₹0.2295
Price ₹0.2800 · Downside -30.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹0.1900 ₹0.2400 ₹0.3200 79
Growth DCF ₹0.2000 ₹0.2500 ₹0.3200 78
5Y EBITDA Exit ₹0.1700 ₹0.2300 ₹0.3100 74
All 15 models by family
DCF Models
FCF DCF ₹0.1900 ₹0.2400 ₹0.3200 79
5Y EBITDA Exit ₹0.1700 ₹0.2300 ₹0.3100 74
5Y P/E Exit ₹0.2100 ₹0.3000 ₹0.4100 69
10Y EBITDA Exit ₹0.1800 ₹0.2200 ₹0.2600 68
10Y P/E Exit ₹0.2000 ₹0.2600 ₹0.3100 63
Earnings-Based
Graham-Dodd ₹0.1100 ₹0.1300 ₹0.1500 65
EPV ₹0.1100 ₹0.1200 ₹0.1300 74
Multiples
P/E Multiple ₹0.2600 ₹0.3500 ₹0.4300 63
P/B Multiple ₹5.52 ₹7.36 ₹9.20 55
EV/EBIT ₹0.2000 ₹0.2700 ₹0.3300 66
EV/EBITDA ₹0.1600 ₹0.2200 ₹0.2800 67
Growth DCF
Growth DCF ₹0.2000 ₹0.2500 ₹0.3200 78
Economic Profit
Residual Income ₹0.8900 ₹0.9400 ₹1.02 68
ROIC Compounder ₹0.1100 ₹0.1200 ₹0.1300 70
Growth Earnings
Growth-Adj P/E ₹0.1800 ₹0.2600 ₹0.3400 65

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 56
Are margins and returns getting better?
Cashflow 88
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 2
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year (last 3 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−16.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−16.6%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2023 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 31%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +10.0% a year for the price.

531752 screens overvalued: fair value 30% below the price. Compare with ST Pharm Co →

Compare Biogen Pharmachem Industries Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 58 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −30.2% · Below median
Profitability
Return on assets 1.0% · Below median

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

Price / free cash flow (fiscal year) 0.2× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 12
FUTURE (revenue growth)0 · sector 68
PAST (return on equity)0 · sector 24
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 26

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 19,430 KRW 47,019 KRW +142% vs 531752
DongKook Pharmaceutical Co 086450 23,050 KRW 28,372 KRW +23% vs 531752
ST Pharm Co 237690 71,200 KRW 61,182 KRW −14% vs 531752
Vivozon Pharmaceutical Co 082800 3,000 KRW 2,179 KRW −27% vs 531752
Oscotec Inc 039200 34,250 KRW 21,262 KRW −38% vs 531752
NatureCell Co 007390 21,950 KRW 11,176 KRW −49% vs 531752
Mezzion Pharma Co 140410 64,500 KRW 31,450 KRW −51% vs 531752
BINEX Co 053030 6,680 KRW 1,844 KRW −72% vs 531752
Caregen Co 214370 27,900 KRW 5,414 KRW −81% vs 531752
SHUKRAPHAR SHUKRAPHAR ₹82.24 ₹9.14 −89% vs 531752

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biogen Pharmachem Industries Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Biogen Pharmachem Industries Limited Fair Value". https://www.fairvalue-calculator.com/stock/531752

Frequently asked questions

Is Biogen Pharmachem Industries Limited (531752) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of ₹0.1955 versus a price of ₹0.2800, about 30% lower (overvalued).
What is the fair value of 531752?
Our model-based fair value for Biogen Pharmachem Industries Limited is ₹0.1955 (as of Nov 16, 2026), built from audited fundamentals. The current price: ₹0.2800.
What is the quality score of 531752?
Biogen Pharmachem Industries Limited has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biogen Pharmachem Industries Limited (531752)?
Our model-based price target is the fair value of ₹0.1955 (as of Nov 16, 2026) from 15 valuation models. Cautious scenario ₹0.1615, optimistic scenario ₹0.2295. It is a calculation from audited fundamentals, not an analyst target.
What is the Biogen Pharmachem Industries Limited stock forecast for 2026?
Our models put fair value at ₹0.1955, about 30% lower versus a price of ₹0.2800 (overvalued). Cautious scenario ₹0.1615, optimistic scenario ₹0.2295. The calculation is refreshed regularly with new filings.
What growth is priced into Biogen Pharmachem Industries Limited (531752)?
For today's price to be fair in a discounted-cash-flow model, Biogen Pharmachem Industries Limited would have to grow free cash flow by 14.6 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue fell 8.5 % per year. As of Nov 16, 2026.
What discount rate (WACC) does the fair value of 531752 use?
Our models discount Biogen Pharmachem Industries Limited at 12.4 %: a base by market capitalisation (nano), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Biogen Pharmachem Industries Limited that is +14.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Biogen Pharmachem Industries Limited (531752) delivered so far?
Over the past 4 years revenue at Biogen Pharmachem Industries Limited shrank 8.5 % a year. The price currently implies free-cash-flow growth of +14.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Biogen Pharmachem Industries Limited (531752) growing?
The median revenue growth in the sector is +11.6 % a year. That is the yardstick for the growth priced into Biogen Pharmachem Industries Limited (+14.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Biogen Pharmachem Industries Limited (531752)?
The free-cash-flow yield on the price is 5.32 %: that much free cash flow Biogen Pharmachem Industries Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Biogen Pharmachem Industries Limited (531752)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biogen Pharmachem Industries Limited it is ₹0.1955 per share (as of Nov 16, 2026), against a price of ₹0.2800. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Biogen Pharmachem Industries Limited stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 531752 trades above its calculated fair value: price ₹0.2800, fair value ₹0.1955, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 531752?
No. The price is what the market pays today (₹0.2800); the fair value is what the company's own numbers justify (₹0.1955). For Biogen Pharmachem Industries Limited the two are ₹0.0845 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biogen Pharmachem Industries Limited worth?
The market values Biogen Pharmachem Industries Limited at about ₹295M (market capitalisation, as of Nov 16, 2026). Per share that is ₹0.2800; our models calculate a fair value of ₹0.1955 per share.
What do the bullish and bearish scenarios say about 531752?
Our models span a range for Biogen Pharmachem Industries Limited: cautious scenario ₹0.1615, base ₹0.1955, optimistic ₹0.2295 per share (as of Nov 16, 2026, price ₹0.2800). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 531752 from its 52-week high?
Biogen Pharmachem Industries Limited trades at ₹0.2800, about 59% below its 52-week high of ₹0.6771 and 17% above the low of ₹0.2400 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹0.1955 is for.
Which stocks are comparable to Biogen Pharmachem Industries Limited?
From the same area (Health Care) we also value ST Pharm Co, Caregen Co, Mezzion Pharma Co, NatureCell Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biogen Pharmachem Industries Limited stock attractive at the current price?
The data as of Nov 16, 2026: price ₹0.2800, calculated fair value ₹0.1955 (−30%), Quality Score 38/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 531752 calculated?
We run Biogen Pharmachem Industries Limited through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹0.1955 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Biogen Pharmachem Industries Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biogen Pharmachem Industries Limited (531752)?
The closing price on Nov 16, 2026 was ₹0.2800. Our model-based fair value is ₹0.1955, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biogen Pharmachem Industries Limited right now?
The price sits above even our optimistic bull case (₹0.2295). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Biogen Pharmachem Industries Limited

How large is the market capitalisation of Biogen Pharmachem Industries Limited (531752)?
The market capitalisation of Biogen Pharmachem Industries Limited is ₹295M (≈ $3.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Biogen Pharmachem Industries Limited (531752)?
Earnings per share at Biogen Pharmachem Industries Limited are ₹−0.0018. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Biogen Pharmachem Industries Limited (531752)?
On an EBIT basis the return on assets of Biogen Pharmachem Industries Limited is 0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much net debt does Biogen Pharmachem Industries Limited (531752) carry?
The net debt of Biogen Pharmachem Industries Limited is ₹534K (fiscal year 2021, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Biogen Pharmachem Industries Limited in the live analysis

One click puts Biogen Pharmachem Industries Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.